IL112051A0 - Methods of inhibiting sexual precocity - Google Patents
Methods of inhibiting sexual precocityInfo
- Publication number
- IL112051A0 IL112051A0 IL11205194A IL11205194A IL112051A0 IL 112051 A0 IL112051 A0 IL 112051A0 IL 11205194 A IL11205194 A IL 11205194A IL 11205194 A IL11205194 A IL 11205194A IL 112051 A0 IL112051 A0 IL 112051A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- sexual precocity
- inhibiting sexual
- inhibiting
- precocity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/171,393 US5451590A (en) | 1993-12-21 | 1993-12-21 | Methods of inhibiting sexual precocity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL112051A0 true IL112051A0 (en) | 1995-03-15 |
Family
ID=22623576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11205194A IL112051A0 (en) | 1993-12-21 | 1994-12-19 | Methods of inhibiting sexual precocity |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5451590A (de) |
| EP (1) | EP0659420A1 (de) |
| JP (1) | JPH07215857A (de) |
| KR (1) | KR950016734A (de) |
| CN (1) | CN1108099A (de) |
| AU (1) | AU8155294A (de) |
| CA (1) | CA2138507A1 (de) |
| CZ (1) | CZ321794A3 (de) |
| HU (1) | HUT71340A (de) |
| IL (1) | IL112051A0 (de) |
| NO (1) | NO944931L (de) |
| NZ (1) | NZ270179A (de) |
| RU (1) | RU94045156A (de) |
| ZA (1) | ZA9410075B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| JPH08510451A (ja) | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 |
| US7209221B2 (en) * | 1994-05-23 | 2007-04-24 | Automotive Technologies International, Inc. | Method for obtaining and displaying information about objects in a vehicular blind spot |
| US5521214A (en) * | 1995-01-25 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting environmental estrogens |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| AU777770C (en) | 1999-05-04 | 2005-11-10 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
| US7852462B2 (en) * | 2000-05-08 | 2010-12-14 | Automotive Technologies International, Inc. | Vehicular component control methods based on blind spot monitoring |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (de) * | 1962-09-13 | |||
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-12-21 US US08/171,393 patent/US5451590A/en not_active Expired - Lifetime
-
1994
- 1994-12-19 JP JP6314553A patent/JPH07215857A/ja active Pending
- 1994-12-19 AU AU81552/94A patent/AU8155294A/en not_active Abandoned
- 1994-12-19 CZ CZ943217A patent/CZ321794A3/cs unknown
- 1994-12-19 KR KR1019940034925A patent/KR950016734A/ko not_active Application Discontinuation
- 1994-12-19 HU HU9403669A patent/HUT71340A/hu unknown
- 1994-12-19 ZA ZA9410075A patent/ZA9410075B/xx unknown
- 1994-12-19 RU RU94045156/14A patent/RU94045156A/ru unknown
- 1994-12-19 EP EP94309478A patent/EP0659420A1/de not_active Ceased
- 1994-12-19 NO NO944931A patent/NO944931L/no unknown
- 1994-12-19 CN CN94119730A patent/CN1108099A/zh active Pending
- 1994-12-19 NZ NZ270179A patent/NZ270179A/en unknown
- 1994-12-19 CA CA002138507A patent/CA2138507A1/en not_active Abandoned
- 1994-12-19 IL IL11205194A patent/IL112051A0/xx unknown
-
1995
- 1995-05-17 US US08/442,707 patent/US5552417A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5451590A (en) | 1995-09-19 |
| NO944931L (no) | 1995-06-22 |
| ZA9410075B (en) | 1996-06-19 |
| RU94045156A (ru) | 1996-10-20 |
| HU9403669D0 (en) | 1995-02-28 |
| CZ321794A3 (en) | 1995-09-13 |
| NZ270179A (en) | 1996-08-27 |
| KR950016734A (ko) | 1995-07-20 |
| HUT71340A (en) | 1995-11-28 |
| AU8155294A (en) | 1995-06-29 |
| CN1108099A (zh) | 1995-09-13 |
| NO944931D0 (no) | 1994-12-19 |
| US5552417A (en) | 1996-09-03 |
| EP0659420A1 (de) | 1995-06-28 |
| JPH07215857A (ja) | 1995-08-15 |
| CA2138507A1 (en) | 1995-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL327569A1 (en) | Promedications of thrombosin inhibitors | |
| PL297904A1 (en) | Method of obtaining bisephenol | |
| IL112031A0 (en) | Methods of inhibiting autoimmune diseases | |
| HU9403669D0 (en) | Methods of inhibiting sexual precocity | |
| PL312470A1 (en) | Method of oximation | |
| PL313740A1 (en) | Method of | |
| IL118574A0 (en) | Methods of inhibiting melanoma | |
| EP0782444A4 (de) | Verfahren zur hemmung von bradykinin-assozierten störungen | |
| IL117036A0 (en) | Methods of inhibiting effects of il-6 | |
| GB9202196D0 (en) | Method of treatment | |
| PL297500A1 (en) | Method of obtaining 4-phenyl-benzophenone | |
| GB9201391D0 (en) | Method of treatment | |
| ZA946331B (en) | Pyran-4-ylmethyl-substituted arylalkylaryl- arylalkenylylaryl- and arylalkynylarylurea inhibitors of 5-lipoxygenase | |
| PL313442A1 (en) | Method of obtaining fesi | |
| TW294938U (en) | Improved structure of acupuncture tool | |
| GB9321971D0 (en) | Method of treatment | |
| GB9321796D0 (en) | Method of treatment | |
| GB9307004D0 (en) | Method of treatment | |
| PL299255A1 (en) | Method of obtaining meproscilarine | |
| ZA942247B (en) | Method of construction | |
| GB9326020D0 (en) | Novel method of treatment | |
| GB9308853D0 (en) | Novel method of treatment | |
| GB9300515D0 (en) | Method of casting | |
| GB9311068D0 (en) | Treatment of gas | |
| GB9309789D0 (en) | Treatment of gas |